Analyses / MU
High-margin chipmaker faces cyclical headwinds; valuation stretched despite solid fundamentals and insider buying restraint.
A free account reveals MU's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Margin profile strong (39.8% gross, 26.1% operating). Memory demand from AI infrastructure secular tailwind. 52-week rebound from $147.61 low shows recovery conviction. Insider buy:sell ratio 1:4 (net restraint, not panic). Forward P/E 122x extreme but reflects trough earnings; if EPS normalizes, multiple should compress into 15–18x range.
▼ Bear Case
Down 5.3% today on 'AI slowdown' chatter; sector-wide pressure. P/S 27.9x, EV/EBITDA 56.3x, price-to-FCF 625x all elevated by cyclical-peak multiples. EPS growth -0.66% YoY despite revenue +6.7% signals margin compression risk. Kioxia $10B US listing threat could add supply/cap upside. Insider sells vastly outpace buys (407 vs 97). Beta 2.37 amplifies sector drawdowns.
Valuation
overvalued_on_cyclical_multiples — score 42/100
Headline P/E 20.7x modest, but forward P/E 122x distorted by EPS trough. P/S 27.9x, EV/EBITDA 56.3x, price-to-FCF 625x all imply market pricing steep near-term growth recovery. If growth stalls, multiples face compression. Historical cyclical lows suggest normalized P/E 14–18x on $60–70 EPS = fair value $840–1260; current $924 in middle of that band but at risk if EPS disappoints.
Technical Levels
Support · $902.60 (Today's low / intraday support) · $880.00 (Psychological / 10-day MA (est.)) · $820.00 (Stop-loss / key breakdown level)
Resistance · $975.26 (Previous close / immediate overhead) · $1,050.00 (3-month target zone) · $1,255.00 (52-week high / significant resistance)
RSI: data_unavailable
Financial Health
Score 78/100. Strong liquidity ratios (current 2.52, quick 1.79) indicate ability to weather downturns. Book value $48.28 implies P/B 19.1x is reasonable given growth. Debt metrics unavailable; full balance sheet required for complete assessment.
Catalysts
| Q4 2024 earnings report / guidance | likely next 4–8 weeks (est.) | high |
| Kioxia US IPO filing / announcement | weeks to months (est.) | medium |
| AI capex cycle confirmation / deceleration | ongoing; quarterly data | high |
| Insider trading pattern shifts | continuous monitoring | medium |
| Analyst upgrades/downgrades on sector rotation | event-driven | medium |
Risk Flags
See MU's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock MU free →Recent News
- Watch Out SKHY, MU, SNDK: Japan's Kioxia Reportedly Eyes $10B US Listing To Ride AI Memory BoomYahoo
- Chip Stocks Sink on AI Slowdown Calls, But Analysts Doubt a Crash Is NearYahoo
- Prediction: Micron Stock Will Hit $1,250 After Sept. 30Yahoo
- Why Micron, Intel, AMD, and Other Chip Stocks Fell TodayYahoo
- Micron (MU) Falls More Steeply Than Broader Market: What Investors Need to KnowYahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full MU analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
MU FAQ
Is MU a buy right now?
Micron Technology Inc's current read is a cyclical_recovery setup with 62 confidence over a 3-6 months horizon. Valuation: overvalued_on_cyclical_multiples. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is MU overvalued?
overvalued_on_cyclical_multiples (valuation score 42/100). Headline P/E 20.7x modest, but forward P/E 122x distorted by EPS trough. P/S 27.9x, EV/EBITDA 56.3x, price-to-FCF 625x all imply market pricing steep near-term growth recovery. If growth stalls, multiples face compression. Historical cyclical lows suggest normalized P/E 14–18x on $60–70 EPS = fair value $840–1260; current $924 in middle of that band but at risk if EPS disappoints.
What are the risks of buying MU?
Down 5.3% today on 'AI slowdown' chatter; sector-wide pressure. P/S 27.9x, EV/EBITDA 56.3x, price-to-FCF 625x all elevated by cyclical-peak multiples. EPS growth -0.66% YoY despite revenue +6.7% signals margin compression risk. Kioxia $10B US listing threat could add supply/cap upside. Insider sells vastly outpace buys (407 vs 97). Beta 2.37 amplifies sector drawdowns.